• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

原理验证:抗毒蕈碱药物对健康受试者膀胱充盈感的影响——使用 4 毫克和 8 毫克托特罗定缓释片进行的安慰剂对照双盲研究。

Proof of principle: The effect of antimuscarinics on bladder filling sensations in healthy subjects--a placebo controlled double blind investigation using 4 and 8 mg tolterodine extended release.

机构信息

Neurourology, Spinal Cord Injury Center, Balgrist University Hospital, Zürich, Switzerland.

出版信息

Neurourol Urodyn. 2010 Mar;29(3):464-9. doi: 10.1002/nau.20743.

DOI:10.1002/nau.20743
PMID:19637377
Abstract

AIMS

There is evidence that antimuscarinic drugs have depressant influence not only on bladder muscle activity, but also on bladder sensations. The aim of this study was to evaluate the effect of a single dose tolterodine extended release (ER) 4 and 8 mg on bladder sensations during filling cystometry.

METHODS

After approval of the local ethics committee, 30 healthy female subjects (23.7 +/- 2.3 years) were included and randomly assigned to three groups: (A) placebo, (B) tolterodine ER 4 mg, and (C) tolterodine ER 8 mg in a double blind manner. Measurements were performed at baseline and 4 hr postmedication in each group, consisting of: (1) Filling cystometry with 25 ml/min at which subjects had to indicate first sensation of filling (FSF), first desire to void (FDV), and strong desire to void (SDV). (2) Uroflowmetry and ultrasound control for residual urine.

RESULTS

In the placebo group, filling volumes at FDV and SDV decreased significantly posttreatment. This effect could not be observed for the tolterodine 8 mg group and only at SDV in the 4 mg group. No significant difference between groups was found regarding uroflowmetry parameters and postvoid residual volume.

CONCLUSIONS

No increase of filling volumes in healthy subjects could be observed with tolterodine. However, the results suggest that tolterodine is able to alleviate irritation caused by repeated catheterization and cystometry. There was no significant influence of tolterodine ER 4 or 8 mg on voiding function.

摘要

目的

有证据表明,抗毒蕈碱药物不仅对膀胱肌肉活动有抑制作用,而且对膀胱感觉也有抑制作用。本研究的目的是评估单剂量托特罗定延长释放(ER)4 毫克和 8 毫克对充盈性膀胱测压时膀胱感觉的影响。

方法

在当地伦理委员会批准后,纳入 30 名健康女性受试者(23.7+/-2.3 岁),并以双盲方式随机分为三组:(A)安慰剂组,(B)托特罗定 ER 4 毫克组,和(C)托特罗定 ER 8 毫克组。在每组中,在基线和用药后 4 小时进行以下测量:(1)以 25 ml/min 的速度进行充盈性膀胱测压,受试者必须在此时指出第一次充盈感(FSF)、第一次排尿感(FDV)和强烈排尿感(SDV)。(2)尿流率和残余尿量的超声检查。

结果

在安慰剂组中,FDV 和 SDV 的充盈量在治疗后显著下降。在托特罗定 8 毫克组中没有观察到这种效果,而仅在 4 毫克组中在 SDV 时观察到。各组之间的尿流率参数和残余尿量无显著差异。

结论

在健康受试者中,托特罗定不能增加充盈量。然而,结果表明,托特罗定能够缓解反复导管插入和膀胱测压引起的刺激。托特罗定 ER 4 毫克或 8 毫克对排尿功能没有显著影响。

相似文献

1
Proof of principle: The effect of antimuscarinics on bladder filling sensations in healthy subjects--a placebo controlled double blind investigation using 4 and 8 mg tolterodine extended release.原理验证:抗毒蕈碱药物对健康受试者膀胱充盈感的影响——使用 4 毫克和 8 毫克托特罗定缓释片进行的安慰剂对照双盲研究。
Neurourol Urodyn. 2010 Mar;29(3):464-9. doi: 10.1002/nau.20743.
2
Does tolterodine extended release affect the bladder electrical perception threshold? A placebo controlled, double-blind study with 4 and 8 mg in healthy volunteers.托特罗定缓释剂是否会影响膀胱电感知阈值?一项针对健康志愿者的安慰剂对照、双盲研究,剂量分别为4毫克和8毫克。
J Urol. 2007 Dec;178(6):2495-500. doi: 10.1016/j.juro.2007.08.043. Epub 2007 Oct 15.
3
The effects of tolterodine on bladder-filling sensations and perception thresholds to intravesical electrical stimulation: method and initial results.托特罗定对膀胱充盈感觉及膀胱内电刺激感知阈值的影响:方法与初步结果
BJU Int. 2007 Sep;100(3):574-8. doi: 10.1111/j.1464-410X.2007.06903.x.
4
Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence.托特罗定缓释制剂治疗男性膀胱过度活动症和急迫性尿失禁的疗效及耐受性
BJU Int. 2006 May;97(5):1003-6. doi: 10.1111/j.1464-410X.2006.06068.x.
5
Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial.托特罗定缓释片治疗以尿急为主的混合性尿失禁:一项随机、安慰剂对照试验
Urology. 2004 Aug;64(2):269-74; discussion 274-5. doi: 10.1016/j.urology.2004.02.029.
6
Efficacy and tolerability of tolterodine extended-release in continent patients with overactive bladder and nocturia.托特罗定缓释剂在膀胱过度活动症伴夜尿症的控尿患者中的疗效和耐受性。
BJU Int. 2006 Jun;97(6):1262-6. doi: 10.1111/j.1464-410X.2006.06146.x.
7
Tolterodine treatment for children with symptoms of urinary urge incontinence suggestive of detrusor overactivity: results from 2 randomized, placebo controlled trials.托特罗定治疗有逼尿肌过度活动迹象的尿急失禁症状儿童:两项随机、安慰剂对照试验的结果
J Urol. 2005 Apr;173(4):1334-9. doi: 10.1097/01.ju.0000152322.17542.63.
8
Tolterodine extended release is efficacious in continent and incontinent subjects with overactive bladder.托特罗定缓释制剂对患有膀胱过度活动症的尿失禁和非尿失禁患者均有效。
Urology. 2008 Sep;72(3):488-93. doi: 10.1016/j.urology.2008.05.019. Epub 2008 Jul 17.
9
Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.托特罗定缓释片对患有膀胱过度活动症和急迫性尿失禁的性活跃女性患者报告结局的影响。
Curr Med Res Opin. 2009 Sep;25(9):2159-65. doi: 10.1185/03007990903103279.
10
Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.血清前列腺特异抗原(PSA)对坦索罗辛联合或不联合托特罗定缓释剂治疗包括膀胱过度活动症(OAB)在内的下尿路症状(LUTS)男性患者疗效的影响。
Urology. 2008 Nov;72(5):1061-7; discussion 1067. doi: 10.1016/j.urology.2008.06.067. Epub 2008 Sep 25.